Eli Lilly says Verzenio extended survival in late-stage breast cancer trial

[Indianapolis - April 2016: Eli Lilly and Company V]
jetcityimage/iStock Editorial via Getty Images

Eli Lilly (NYSE:LLY [https://seekingalpha.com/symbol/LLY]) announced on Wednesday that its FDA-approved antitumor agent Verzenio, as part of a combination regimen, improved overall survival in a late-stage trial for certain patients with breast cancer.

The findings were based on a primary overall survival (OS) analysis of its Phase 3 monarchE trial, which involved more than 5,500 patients with hormone receptor-positive (HR+), HER2-, node-positive, high-risk early breast cancer across the globe.

Citing topline data, the Indiana-based drugmaker said that Verzenio plus endocrine therapy improved OS, a key secondary endpoint in monarchE, with a statistically significant and clinically meaningful effect versus endocrine therapy alone.

The analysis also indicated that the orally administered therapy sustained benefit in several clinical measures, including invasive disease-free survival, the study’s primary endpoint.

“These data validate Verzenio as the standard-of-care for patients with node-positive, high-risk disease and increase the urgency to ensure all eligible patients are treated,” said Jacob Van Naarden, head of Lilly Oncology.

The company plans to present the data at a future medical event. It will also submit the findings for publication in a peer-reviewed journal and discuss the results with the global regulatory agencies. [https://seekingalpha.com/pr/20212719-lillys-verzenio-abemaciclib-increases-overall-survival-in-hr-her2-high-risk-early-breast]

MORE ON ELI LILLY

* Eli Lilly Vs. Novo Nordisk: One Stock Is Massively Undervalued, The Other Overvalued [https://seekingalpha.com/article/4816247-eli-lilly-vs-novo-nordisk-one-stock-is-massively-undervalued-the-other-overvalued]
* Pharmaceuticals Industry Analysis: Eli Lilly Tops My Tier Two [https://seekingalpha.com/article/4815108-pharmaceuticals-industry-analysis-eli-lilly-tops-my-tier-two]
* Novo Nordisk's Loss Is Eli Lilly's Gain, And Vice Versa [https://seekingalpha.com/article/4814582-novo-nordisk-loss-is-eli-lilly-gain-and-vice-versa]
* Chugai spikes after Eli Lilly trial win for obesity pill [https://seekingalpha.com/news/4489466-chugai-stock-spikes-eli-lilly-trial-win-obesity-pill]
* RFK Jr. says negotiations to lower drug prices are at an advanced stage [https://seekingalpha.com/news/4489276-rfk-jr-says-talks-lower-drug-prices-advanced-stage]